Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Tsoi

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
The Journal of Clinical Investigation|April 29, 2021
Melanoma dedifferentiation induced by IFN-γ epigenetic remodeling in response to anti-PD-1 therapyYeon Joo Kim, Katherine M Sheu, Jennifer Tsoi, et al.
Nature Communications|December 16, 2014
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanomaJudith Müller, Oscar Krijgsman, Jennifer Tsoi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2018
A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without IpilimumabTheodore S Nowicki, Beata Berent-Maoz, Gardenia Cheung-Lau, et al.
Nature Communications|February 2, 2020
Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonistGiulia Parisi, Justin D Saco, Felix B Salazar, et al.
Nature Cancer|August 9, 2021
PAK4 inhibition improves PD-1 blockade immunotherapyGabriel Abril-Rodriguez, Davis Y Torrejon, Wei Liu, et al.
Cancer Discovery|May 30, 2020
Overcoming Genetically Based Resistance Mechanisms to PD-1 BlockadeDavis Y Torrejon, Gabriel Abril-Rodriguez, Ameya S Champhekar, et al.
Nature Cancer|February 5, 2022
Publisher Correction: PAK4 inhibition improves PD-1 blockade immunotherapyGabriel Abril-Rodriguez, Davis Y Torrejon, Wei Liu, et al.
Scientific Reports|September 14, 2024
MITF regulates IDH1, NNT, and a transcriptional program protecting melanoma from reactive oxygen speciesElisabeth Roider, Alexandra I T Lakatos, Alicia M McConnell, et al.
Science (New York, N.Y.)|April 6, 2013
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cellsDan Rohle, Janeta Popovici-Muller, Nicolaos Palaskas, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2023
MITF regulates IDH1 and NNT and drives a transcriptional program protecting cutaneous melanoma from reactive oxygen speciesElisabeth Roider, Alexandra I T Lakatos, Alicia M McConnell, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
The Journal of Clinical Investigation|April 29, 2021
Melanoma dedifferentiation induced by IFN-γ epigenetic remodeling in response to anti-PD-1 therapyYeon Joo Kim, Katherine M Sheu, Jennifer Tsoi, et al.
Nature Communications|December 16, 2014
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanomaJudith Müller, Oscar Krijgsman, Jennifer Tsoi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2018
A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without IpilimumabTheodore S Nowicki, Beata Berent-Maoz, Gardenia Cheung-Lau, et al.
Nature Communications|February 2, 2020
Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonistGiulia Parisi, Justin D Saco, Felix B Salazar, et al.
Nature Cancer|August 9, 2021
PAK4 inhibition improves PD-1 blockade immunotherapyGabriel Abril-Rodriguez, Davis Y Torrejon, Wei Liu, et al.
Cancer Discovery|May 30, 2020
Overcoming Genetically Based Resistance Mechanisms to PD-1 BlockadeDavis Y Torrejon, Gabriel Abril-Rodriguez, Ameya S Champhekar, et al.
Nature Cancer|February 5, 2022
Publisher Correction: PAK4 inhibition improves PD-1 blockade immunotherapyGabriel Abril-Rodriguez, Davis Y Torrejon, Wei Liu, et al.
Scientific Reports|September 14, 2024
MITF regulates IDH1, NNT, and a transcriptional program protecting melanoma from reactive oxygen speciesElisabeth Roider, Alexandra I T Lakatos, Alicia M McConnell, et al.
Science (New York, N.Y.)|April 6, 2013
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cellsDan Rohle, Janeta Popovici-Muller, Nicolaos Palaskas, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2023
MITF regulates IDH1 and NNT and drives a transcriptional program protecting cutaneous melanoma from reactive oxygen speciesElisabeth Roider, Alexandra I T Lakatos, Alicia M McConnell, et al.
Pageof 4